The case for more cautious, patient-focused antiretroviral therapy

Annals of Internal Medicine

Volumn 132, Issue 4, 2000, Pages 306-311

  Henry, Keith ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; STAVUDINE; VIRUS RNA;

DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LIVER INJURY; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT PLANNING;

EID: 0034652040     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-132-4-200002150-00009     Document Type: Review

References (75)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-60.
2. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA. 1998; 280:78-86.
3. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. MMWR Morb Mortal Wkly Rep. 1998;47:43-82.
4. http://www.hivatis.org.
5. Holmes SA. 1997 AIDS deaths in US fall by almost half. New York Times. 8 Oct 1998:A1.
6. + lymphocytes as prognostic markers of HIV-1 infection Ann Intern Med. 1997;126:946-54.
7. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4+ lymphocytes in HIV-1 infection Nature 1995;373:123-6.
8. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337:725-33.
9. Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-1 infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA. 1998;279:930-7.
10. Cameron B, Heath-Chiozzi M, Kravik S, Kravcik S, Mills R, Potthoff A, et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir [Abstract]. Third Conference on Retroviruses and Opportunistic Infections. 1996:LB6a.
11. Ho DD. Time to hit HIV, early and hard [Editorial]. N Engl J Med. 1995;333: 450-1.
12. Fauci A. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science. 1993;262:1011-8.
13. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112-6.
14. Zhang ZQ, Notermans DW, Sedgewick G, Cavert W, Wietgrefe S, Zupancic M, et al. Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci U S A. 1998;95:11S4-9.
15. Zhang ZQ, Shuler T, Cavert W, Nottermans DW, Gebhard K, Henry K, et al. Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection. Proc Natl Acad Sci U S A. 1999; 96:5169-72.
16. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, et al. Vigorous HIV-1-specific CD4+ T cells responses associated with control of viremia. Science. 1997;278:1447-50.
17. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature. 1998;396:690-5.
18. Notermans DW, Pakker NG, Hamann D, Foudraine NA, Kauffmann RH, Meenhorst PL, et al. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults. J Infect Dis. 1999;180:1050-6.
19. Kempf DJ, Rode RA, Xu Y, Sun E, Heath-Chiozzi ME, Valdes J, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS. 1998;12:F9-F14.
20. Demeter L, Hughes M, Fischl M, Grimes J, Bosch R, Squires K. et al. Predictors of virologic and clinical responses to indinavir + ZDV + 3TC or ZDV + 3TC [Abstract]. Fifth Conference on Retroviruses and Opportunistic Infections. 1998:509.
21. Henry K, Melroe H, Simpson J, Kane E, Stawarz K, Erice A, et al. Levels of plasma HIV RNA measured by the Roche ultrasensitive assay in HIV-infected individuals with HIV RNA below the bDNA detection limit [Abstract]. Fifth Conference on Retroviruses and Opportunistic Infections. 1998:529.
22. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999;340:1605-13.
23. Hockett RD, Kilby M, Derdeyn CA, Saag MS, Sillers M, Squires K, et al. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med. 1999;189:1545-54.
24. Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS. 1998;12:2161-7.
25. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-7.
26. Erice A, Mayers DL, Strike DG, Sannerud KJ, McCutchan FE, Henry K, et al. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med. 1993;328:1163-5.
27. Hecht FM, Grant RM, Petropoulos CJ, Dillon B, Chesney MA, Tian H, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998;339:307-11.
28. Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, et al. HIV-1 drug resistance in newly infected individuals. JAMA. 1999;282:1135-41.
29. Little SJ, Daar ES, D'Aquila RT, Keiser PH, Connick E, Whitcomb JM, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA. 1999;282:1142-9.
30. Pomerantz RJ. Primary HIV-1 resistance-a new phase in the epidemic? [Editorial] JAMA. 1999;282:1177-9.
31. Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel. JAMA. 1998;279:1984-91.
32. Jurriaans S, Van Gemen B, Weverling GJ, Van Strijp D, Nara P, Coutinho R, et al. The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology. 1994;204: 223-33.
33. Kimata JT, Kuller L, Anderson DB, Dailey P, Overbaugh J. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat Med. 1999;5:535-41.
34. Hirsch VM. Evolution of the fittest ends in tragedy. Nat Med. 1999;5:488-9.
35. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167-70.
36. Katzenstein D, Kim S, Hughes M, Hammer S, Gegruttola V. HIV serum RNA, CD4 cell numbers and risk for clinical endpoints in a case-cohort study of ACTG 175 [Abstract]. 12th World AIDS Conference. 1998:507/12124.
37. Lyles R, Munoz A, Bazmi H, Yamashita T, Detels R, Rinaldo C, et al. Natural history of HIV-1 viremia after seroconversion in the Multicenter AIDS Cohort Study [Abstract]. Sixth Conference on Retroviruses and Opportunistic Infections 1999:273.
38. Haase AT, Henry K, Zupanic M, Sedgewick G, Faust RA, Melroe H, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science. 1996;274:985-9.
39. Cavert W, Notermans DW, Staskus K, Wietgrefe SW, Zupancic M, Gebhard K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science. 1997;276:960-4.
40. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512-7.
41. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med. 1999; 340:1614-22.
42. Pomerantz RJ. Residual HIV-1 disease in the era of highly active antiretroviral therapy. N Engl J Med. 1999;340:1672-4.
43. Chun TW, Engel D, Mizell SB, Hallahan CW, Fischette M, Park S, et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1 infected patients receiving highly active anti-retroviral therapy. Nat Med. 1999;5:651-5
44. Davey R, Bhat N, Yoder C, Dewar R, Lempicki R, Metcalf J, et al. The NoHRT trial: a prospective study of cessation of HAART in HIV-infected patients after prolonged viral suppression [Abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1999:689.
45. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1 infected individuals remaining viraemic with highly effective antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet. 1998;351:723-4.
46. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study Lancet. 1999;353:863-8.
47. Deeks S, Beatty G, Cohen PT, Grant R, Volberding P. Viral load and CD4+ T cell changes in patients failing potent protease inhibitor therapy [Abstract]. Fifth Conference on Retroviruses and Opportunistic Infections 1998:419.
48. Havlir DV, Hellman NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA. 2000;283:229-34.
49. Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA. 2000;283:205-11.
50. Paterson D, Swindells S, Mohr J, Brester M, Vergis E, Squier C, et al. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMS caps [Abstract]. Sixth Conference on Retroviruses and Opportunistic Infections. 1999:92.
51. Fletcher CV, Acosta EP, Henry K, Page LM, Gross CR, Kawle SP, et al. Concentration-controlled zidovudine therapy. Clin Pharmacol Ther. 1998;64: 331-8.
52. Fletcher CV, Kakuda TN, Anderson PL, Henry K, Schacker T, Brundage RC. Viral dynamics of concentration-targeted vs. standard dose therapy with zidovudine, lamivudine, and indinavir [Abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1999:322.
53. Acosta EP, Henry K, Baken L, Page LM, Fletcher CV. Indinavir concentrations and antiviral effect. Pharmacotherapy. 1999;19:708-12.
54. Tebas P, Patick AK, Kane EM, Klebert MK, Simpson JH, Erice A, et al. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS. 1999;13:F23-F28.
55. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
56. Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swensen L, et al. Severe premature coronary artery disease with protease inhibitors. Lancet. 1998;351:1328.
57. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet. 1998;352:1331-2.
58. Diez-Roux AV, Northridge ME, Morabia A, Bassett MT, Shea S. Prevalence and social correlates of cardiovascular disease risk factors in Harlem. Am J Public Health. 1999;89:302-7.
59. Scribner AN, Skiest DJ, Marcantonio D, Hamid F, Troia-Cancio PV, et al. A case control study of osteonecrosis in HIV [Abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1999:1311.
60. Hodak SP, Fluhme D, Kumar P, Nascone J, Evans B, Timpone JG. Avascular necrosis and protease exposure [Abstract]. 39th Interscience Conference on Antimicrobial Agents and Cnemotherapy. 1999:1312.
61. Brinkman K, Ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998;12:1735-44.
62. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659-67.
63. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999;354:1084-9.
64. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nudeoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354:1112-5.
65. Richman DD. Human immunodeficiency virus. Playing chess with reverse transcriptase. Nature. 1993;361:588-9.
66. Levy JA. Caution: should we be treating HIV infection early? Lancet. 1998; 352:982-3.
67. Harrington M. Cure: myth or reality? [Abstract] 12th World AIDS Conference. 1998:159.
68. Lori F, Jessen H, Foli A, Lisziewicz J, Matteo PS. Long-term suppression of HIV-1 by hydroxyurea and didanosine [Letter]. JAMA. 1997;277:1437-8.
69. Molina JM, Chene G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, et al. The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both regimens in previously untreated patients infected with human immunodeficiency virus. J Infect Dis. 1999;180:351-8.
70. Garrrett L. The virus at the end of the world. Esquire. 1999;313:102-72.
71. Fauci AS. The AIDS epidemic - considerations for the 21st century. N Engl J Med. 1999;341:1046-50.
72. Keiser P, Kvanli ME, Turner D, Nassar NN. Cost of HIV care increasing after an initial cost decrease associated with protease inhibitor usage [Abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1999:602.
73. Cooper DA, Emery S. Therapeutic strategies for HIV infection - time to think hard. N Engl J Med. 1998;339:1319-21.
74. As treatment euphoria ebbs, stubborn uncertainties resurface out are unlikely to be resolved soon. Treatment Action Group. TAGIine. 1999;6:1-7.
75. Gazzard BG. Hit soft, hit later [Abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1999 1888.